George K. Ng - 30 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Executive Officer, Director
Signature
/s/ George Ng, by Neda A. Sharifi, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
30 Jan 2024
Net transactions value
+$27,000
Form type
4
Filing time
31 Jan 2024, 16:37:40 UTC
Previous filing
12 Oct 2023
Next filing
22 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $27,000 +10,000 +100% $2.70 20,000 30 Jan 2024 By Family Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Reflects that shares previously reported as directly held by the reporting person were held in a trust.